 Despite evidence of effectiveness for cow's milk, CM, allergy treatment through oral immunotherapy, OIT, frequent adverse events occur, and there are only a few low-powered randomized controlled trials with limited evidence levels. Additionally, clinical tolerance by OIT is not well-defined, and standardized protocols are lacking in pediatric allergy guidelines from several countries. However, the combination of OIT with a melissimab and less allergenic-heated CM products may resolve these problems in the future. This article was authored by Shouichiro Tanyuchi, Messiah Tokahoshi, Kazukiko Sejima, and others.